Artgen Biotech did not extend the deadline for the placement of additional shares in the amount of 17,354,549 shares, refusing to increase the authorized capital. To finance the group's plans for 2024-2026, the company decided to use profits and capital raising in group companies. Against the background of high interest rates and undervalued stock market assets, this approach is more attractive for our shareholders, commented Sergey Masyuk, CEO of Artgen Biotech.